Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 in Relapsed/Refractory Multiple Myeloma
NCT02182141Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2003
- Primary completion
- Mar 2005
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in multiple myeloma (MM), sponsored by Boehringer Ingelheim. Primary endpoint: Maximum Tolerated Dose up to 11 months. Started Apr 2003; status: completed.
02
Drugs
nintedanib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02182141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182141.